Foundayo coupons: which one you can actually use

Two completely different things get called a coupon, and confusing them costs people hundreds of dollars a month. The first is the manufacturer savings card, which can bring Foundayo down to as little as $0–$25 a month — but only if you have commercial or employer insurance. Federal anti-kickback law forbids manufacturers from offering it to anyone on Medicare, Medicaid or TRICARE, which excludes a great many of the people who need it most. The second is a pharmacy discount coupon of the GoodRx or SingleCare kind. Anyone can use one, including Medicare patients, because it is simply a cash price rather than an insurance benefit — but you cannot run it alongside your insurance or on top of the manufacturer card. It is one route per prescription, not a stack. So: if you have commercial insurance, the manufacturer card almost always beats a discount coupon. If you are on Medicare or Medicaid, the card is off the table by law and your real choices are a pharmacy discount coupon or paying the manufacturer directly. The table below shows exactly which path is open to you.

At launch, LillyDirect self-pay starts at about $149/month for the lowest dose — the cheapest cash entry price among FDA-approved GLP-1s. Higher doses cost more, so your real monthly cost depends on the dose you titrate to. Verify the current per-dose pricing on LillyDirect before ordering.

Yes. Lilly launched Foundayo with a savings card that can bring eligible commercially insured patients to as low as about $25/month, subject to the usual caps and terms. Like all manufacturer copay cards, it is not valid for Medicare, Medicaid, or other government insurance. Activate it via foundayo.lilly.com.

Lilly announced that eligible Medicare Part D patients may be able to get Foundayo for about $50/month beginning as soon as July 1, 2026 — a notable exception in a category where copay cards are barred for Medicare. Confirm with your Part D plan, since manufacturer announcements and plan formularies are not the same thing.

At the entry dose, yes: ~$149/month self-pay undercuts Wegovy (~$499/mo via NovoCare) and Zepbound (~$349–$499/mo via LillyDirect vials). Two honest caveats: Foundayo self-pay rises with dose, and in trials the injectables produced larger average weight loss — Zepbound averaged ~21% at the top dose versus orforglipron's ~11-12% at 72 weeks. Cheapest per month is not the same as cheapest per pound lost.